Implementation of a Fully Automated & Integrated Continuous Biomanufacturing

Logo
Presented by

Irina Ramos at AstraZeneca and Britta Anderson at Merck

About this talk

Development and Implementation of a Fully Automated and Integrated System to Enable Continuous Biomanufacturing for Clinical Scale There are many excellent and well-considered reasons for implementing next generation manufacturing (NGM). We have found that, for the most part, organizations will not fund NGM unless the implementation benefits the funding organization by providing a return of cash, time or needed capability. We will provide examples from the AstraZeneca development of NGM where the platform process proposed was based on a common framework for integrated and continuous biomanufacturing. This framework presents a new system that fully integrates and automates several unit operations, providing flexibility and easy implementation. Here we present the optimized process fit, sterility and bioburden control strategy, and automation features that allow this equipment to be tested for 14 days of continuous end-to-end process operation at the clinical manufacturing scale. We include implementation strategy for adoption in GMP manufacturing
Related topics:

More from this channel

Upcoming talks (13)
On-demand talks (346)
Subscribers (35754)
BioPharma Webinars aims to keep its global audience abreast of all developments in the areas of Drug Development, Manufacturing, Quality Assurance, Outsourcing and Regulatory Affairs, with only the highest quality webinars, presented by the most respected people, working with companies in Pharmaceutical, Biopharmaceutical, Biologics and Biotech Industry.